Home » ABRAXIS BIOSCIENCE RECEIVES MILESTONE PAYMENT FROM TAIHO PHARMACEUTICAL CO.
ABRAXIS BIOSCIENCE RECEIVES MILESTONE PAYMENT FROM TAIHO PHARMACEUTICAL CO.
Abraxis BioScience, Inc., an integrated, global biopharmaceutical company, today announced that it has received a $3 million milestone payment from Taiho Pharmaceutical Co., Ltd., (Taiho), for initiation of a Phase 1 clinical trial for ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060713005121&newsLang=en)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct